Imvax Revenue and Competitors
Estimated Revenue & Valuation
- Imvax's estimated annual revenue is currently $4.6M per year.
- Imvax's estimated revenue per employee is $77,500
- Imvax's total funding is $166.7M.
Employee Data
- Imvax has 59 Employees.
- Imvax grew their employee count by -5% last year.
Imvax's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Legal Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Co-Founder, Chief Medical Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
Imvax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Imvax?
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company's lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
keywords:N/A
$166.7M
Total Funding
59
Number of Employees
$4.6M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Imvax News
About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole...
PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ -- Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM), today announced publication of Phase 1b clinical trial results in Clinical Cancer Research, a journal of the American Asso ...
Imvax, Inc., a Philadelphia, PA-based clinical-stage biotechnology company, raised $112m in Series C financing. The round was led by existing investor HP WILD Holding AG, with participation from other major shareholders – Ziff Capital Partners, Magnetar Capital, and TLP Investment Partners and ...
Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM), and whose proprietary technology has the potential to advance care for patients with serious, unmet medical n ...
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 59 | -17% | N/A |
#2 | $7.5M | 59 | 18% | N/A |
#3 | $7.4M | 59 | -21% | N/A |
#4 | $14.3M | 59 | 7% | N/A |
#5 | $14.3M | 59 | 11% | N/A |